Publications : les Centres SLA sont très impliqués dans la recherche

Les 18 Centres de recours et de Compétences SLA, coordonnés par des médecins neurologues, définis dans le Plan National Maladies Rares (PNMR) participent à des travaux de recherche dans le cadre de collaborations scientifiques nationales et internationales. Cette collaboration donne lui à des publications dans des revues spécialisées qui valident l’intérêt des résultats.

Voici les dernières en dates
Partagez
Imprimer

ATXN2 trinucleotide repeat length correlates with risk of ALS.

Sproviero W, Shatunov A, Stahl D, Shoai M, van Rheenen W, Jones AR, Al-Sarraj S, Andersen PM, Bonini NM, Conforti FL, Van Damme P,

Daoud H, Del Mar Amador M, Fogh I, Forzan M, Gaastra B, Gellera C, Gitler AD, Hardy J, Fratta P, La Bella V, Le Ber I, Van Langenhove T, Lattante S, Lee YC, Malaspina A, Meininger V, Millecamps S, Orrell R, Rademakers R, Robberecht W, Rouleau G, Ross OA, Salachas F, Sidle K, Smith BN, Soong BW, Sorarù G, Stevanin G, Kabashi E, Troakes C, van Broeckhoven C, Veldink JH, van den Berg LH, Shaw CE, Powell JF, Al-Chalabi A. Neurobiol Aging. 2017 Mar;51:178.

 

Motor-evoked potential gain is a helpful test for the detection of corticospinal tract ysfunction in amyotrophic lateral sclerosis.

Duclos Y, Grapperon AM, Jouve E, Truillet R, Zemmour C, Verschueren, A, Pouget J, Attarian S. Clin Neurophysiol. 2017 Feb;128(2):357-364.

 

Are electrophysiological features related to disability in patients with anti-MAGneuropathy?

Gesquière-Dando A, Delmont E, Launay M, Boucraut J, Attarian S.Neurophysiol Clin. 2017 Feb 1.

 

Global Motor Unit Number Index sum score for assessing the loss of lower motor neurons in amyotrophic lateral sclerosis.

Grimaldi S, Duprat L, Grapperon AM, Verschueren A, Delmont E, Attarian S. Muscle Nerve. 2017 Feb 6. Validity of medico-administrative data related to amyotrophic lateral sclerosis in France: A population-based study. Vasta R, Boumédiene F, Couratier P, Nicol M, Nicoletti A, Preux PM, Marin B; Fralim Consortium. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):24-31.

 

Initiation of non-invasive ventilation in amyotrophic lateral sclerosis and clinical practice guidelines: Single-centre, retrospective, descriptive study in a national reference centre.

Georges M, Golmard JL, Llontop C, Shoukri A, Salachas F, Similowski T, Morelot-Panzini C, Gonzalez-Bermejo J. AmyotrophLateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):46-52.

 

A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS.

Corcia P, Danel V, Lacour A, Beltran S, Andres C, Couratier P, Blasco H, Vourc’h P. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Jan 5:1-4.

 

Wildtype motoneurons, ALS-Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling.

Madji Hounoum B, Mavel S, Coque E, Patin F, Vourc’h P, Marouillat, S, Nadal-Desbarats L, Emond P, Corcia P, Andres CR, Raoul C, Blasco H. Glia. 2017 Jan 31.

 

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised,

double-blind, placebo-controlled, phase 2 trial. Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group..Lancet Neurol. 2017 Jan 27.

 

ALS-causing mutations differentially affect PGC-1Α expression and function in the brain vs. peripheral tissues.

Bayer H, Lang K, Buck E, Higelin J, Barteczko L, Pasquarelli N, Sprissler J, Lucas T, Holzmann K, Demestre M, Lindenberg KS, Danzer KM, Boeckers T, Ludolph AC, Dupuis L, Weydt P, Witting A. Neurobiol Dis. 2017 Jan;97(Pt A):36-45.

 

Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study.

Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, Vourc’h P, Andres CR, Corcia P. Can J Neurol Sci.

2017 Jan;44(1):90-95.

 

Disruption of TCA Cycle and Glutamate Metabolism Identified by Metabolomics in an In Vitro Model of Amyotrophic Lateral Sclerosis.

Veyrat-Durebex C, Corcia P, Piver E, Devos D, Dangoumau A, Gouel F, Vourc’h P, Emond P, Laumonnier F, Nadal-Desbarats L, Gordon PH, Andres CR, Blasco H. Mol Neurobiol. 2016 Dec;53(10):6910-6924.

 

Retraction Note to: A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD.

Hukema RK, Riemslagh FW, Melhem S, van der Linde HC, Severijnen LW, Edbauer D, Maas A, Charlet-Berguerand N, Willemsen R, van Swieten JC. Acta Neuropathol Commun. 2016 Dec 9;4(1):129.

 

The Use of Peripherally Inserted Central Catheter in Amyotrophic Lateral Sclerosis Patients at a Later Stage.

Juntas-Morales R, Pageot N, Alphandéry S, Camu W. Eur Neurol. 2017;77(1-2):87-90.

 

Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis.

Ohta Y, Soucy G, Phaneuf D, Audet JN, Gros-Louis F, Rouleau GA, Blasco H, Corcia, P, Andersen PM, Nordin F, Yamashita T, Abe K, Julien JP. Hum Mol Genet. 2016 Nov 1;25(21):4771

Partagez
Imprimer